Bendamustine-rituximab:  a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.

S Dewilde, Beth Woods, JG Castaigne, C. Parker, W. Dunlop

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	111-124
Journal	Journal of Medical Economics
Volume	17
Issue number	2
Early online date	13 Jan 2014
DOIs	https://doi.org/10.3111/13696998.2013.873044
Publication status	Published - 2014

Access to Document

@article{7802b6b6a790453a9e955f4da084f131,

title = "Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.",

author = "S Dewilde and Beth Woods and JG Castaigne and C. Parker and W. Dunlop",

year = "2014",

doi = "10.3111/13696998.2013.873044",

language = "English",

volume = "17",

pages = "111--124",

journal = "Journal of Medical Economics",

issn = "1369-6998",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Bendamustine-rituximab

T2 - a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.

AU - Dewilde, S

AU - Woods, Beth

AU - Castaigne, JG

AU - Parker, C.

AU - Dunlop, W.

PY - 2014

Y1 - 2014

U2 - 10.3111/13696998.2013.873044

DO - 10.3111/13696998.2013.873044

M3 - Article

SN - 1369-6998

VL - 17

SP - 111

EP - 124

JO - Journal of Medical Economics

JF - Journal of Medical Economics

IS - 2

ER -